ストックスクリーナーアプリを入手
8.25
1.23%
0.10
前日終値:
$8.15
開ける：
$8.28
24時間の取引高:
965.54K
Relative Volume:
0.49
時価総額：
$628.49M
収益：
-
当期純損益:
$-168.09M
株価収益率:
-3.8018
EPS:
-2.17
ネットキャッシュフロー:
$-138.01M
1週間 パフォーマンス:
-0.36%
1か月 パフォーマンス:
+11.64%
6か月 パフォーマンス:
-58.69%
1年 パフォーマンス:
-58.73%
1日の値動き範囲:
$8.1901
$8.355
1週間の範囲:
$7.87
$8.55
52週間の値動き範囲:
$6.98
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
名前
Kura Oncology Inc
セクター
電話
(858) 500-8800
住所
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
KURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.25 | 628.49M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-14 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-08-11 | 開始されました | BofA Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-05-17 | 開始されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2022-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 開始されました | Jefferies | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-11-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-11-09 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-13 | 再開されました | Leerink Partners | Outperform |
| 2016-01-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-30 | 開始されました | Oppenheimer | Outperform |
| 2015-12-16 | 開始されました | Citigroup | Buy |
すべてを表示
Kura Oncology Inc (KURA) 最新ニュース
Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $27.13 - MarketBeat
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Will Kura Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan
Kura Oncology (KURA) to Release Earnings on Tuesday - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Weekly Investment Analysts’ Ratings Updates for Kura Oncology (KURA) - Defense World
Kura Oncology's SWOT analysis: stock poised for pivotal year ahead - MSN
Barclays PLC Acquires 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
FY2029 Earnings Forecast for Kura Oncology Issued By Wedbush - MarketBeat
Leerink Partnrs Estimates Kura Oncology Q1 Earnings - MarketBeat
Jennison Associates LLC Purchases New Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
BTIG Research Downgrades Kura Oncology (NASDAQ:KURA) to Neutral - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's What Happened - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Kura Oncology (NASDAQ:KURA) Price Target Raised to $40.00 - MarketBeat
Barclays PLC Buys 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Leerink Partnrs Predicts Kura Oncology Q2 Earnings - MarketBeat
Leerink Partnrs Predicts Kura Oncology Q1 Earnings - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Kura Oncology Inc (KURA) - SETE News
Kura Oncology stock target raised to $40 by H.C. Wainwright - MSN
BTIG cuts Kura Oncology stock rating to Neutral - MSN
Kura Oncology (NASDAQ:KURA) Trading 6.7% HigherStill a Buy? - MarketBeat
Leerink Partnrs Comments on Kura Oncology Q2 Earnings - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology reports inducement grants under Nasdaq listing rule - TipRanks
Kura Oncology Expands Team with Strategic Stock Options PackageInside the $8.25/Share Deal - StockTitan
Kura/Kyowa Kirin’s Ziftomenib Scores In NPM1m AML, But Differentiation Is Key - News & Insights
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML - BioWorld Online
SG Americas Securities LLC Buys New Shares in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies - Benzinga India
Kura Oncology falls despite trial success; rival Syndax gains - Seeking Alpha
Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data - Fierce Biotech
Market Watch Highlights: Kura Oncology Inc (KURA) Ends on an Upturn Note at 9.05 - The Dwinnex
Kura Oncology price target raised to $36 from $34 at Wedbush - TipRanks
BTIG cuts Kura Oncology stock rating to Neutral By Investing.com - Investing.com South Africa
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed - BioSpace
A new trading data show Kura Oncology Inc (KURA) is showing positive returns. - SETE News
Kura stock slides 7% following ziftomenib update - MSN
Kura to take AML drug ziftomenib to regulators after mid-stage win - The Pharma Letter
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs - The Manila Times
Senior Director, Investor Relations - Built In
Kura stock slides 7% following ziftomenib update (KURA:NASDAQ) - Seeking Alpha
Kura Oncology And Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial - Marketscreener.com
Kura Oncology Inc (KURA) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):